Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients
Authors:
- Lukasz SzarpakLukasz Szarpak
- Marcin LapinskiMLMarcin Lapinski
- Aleksandra GaseckaAleksandra Gasecka
- Michal PrucMPMichal Pruc
- Wiktoria L. DrelaWDWiktoria L. Drela
- Mariusz KodaMKMariusz Koda
- Andrea DenegriADAndrea Denegri
- Frank W. PeacockFPFrank W. Peacock
- Miłosz J. JaguszewskiMJMiłosz J. Jaguszewski
- Krzysztof J. FilipiakKrzysztof J. Filipiak
Open Access
- 27 December 2021
- journal article
- review article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (1) , 6
Abstract
Diagnosis of acute coronary syndrome (ACS) based on copeptin level may enable one to confirm or rule-out acute myocardial infarction (AMI) with higher sensitivity and specificity, which may in turn further reduce mortality rate and decrease the economic costs of ACS treatment. We conducted a systematic review and meta-analysis to investigate the relationship between copeptin levels and type of ACS. We searched Scopus, PubMed, Web of Science, Embase, and Cochrane to locate all articles published up to 10 October 2021. We evaluated a meta-analysis with random-effects models to evaluate differences in copeptin levels. A total of 14,139 patients (4565 with ACS) were included from twenty-seven studies. Copeptin levels in AMI and non-AMI groups varied and amounted to 68.7 ± 74.7 versus 14.8 ± 19.9 pmol/L (SMD = 2.63; 95% CI: 2.02 to 3.24; p < 0.001). Copeptin levels in the AMI group was higher than in the unstable angina (UAP) group, at 51.9 ± 52.5 versus 12.8 ± 19.7 pmol/L (SMD = 1.53; 95% CI: 0.86 to 2.20; p < 0.001). Copeptin levels in ST-elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction (NSTEMI) patient groups were 54.8 ± 53.0 versus 28.7 ± 46.8 pmol/L, respectively (SMD = 1.69; 95% CI: = 0.70 to 4.09; p = 0.17). In summary, elevated copeptin levels were observed in patients with ACS compared with patients without ACS. Given its clinical value, copeptin levels may be included in the assessment of patients with ACS as well as for the initial differentiation of ACS.Keywords
This publication has 49 references indexed in Scilit:
- Early rule out of acute myocardial infarction in ED patients: value of combined high-sensitivity cardiac troponin T and ultrasensitive copeptin assays at admissionThe American Journal of Emergency Medicine, 2013
- Release Kinetics of Copeptin in Patients Undergoing Transcoronary Ablation of Septal HypertrophyClinical Chemistry, 2013
- Additional diagnostic and prognostic value of copeptin ultra-sensitive for diagnosis of non-ST-elevation myocardial infarction in older patients presenting to the emergency department1)Clinical Chemistry and Laboratory Medicine (CCLM), 2013
- Combination of Copeptin and Troponin Assays to Rapidly Rule Out Non‐ST Elevation Myocardial Infarction in the Emergency DepartmentAcademic Emergency Medicine, 2012
- Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospitalVascular Health and Risk Management, 2011
- C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) studyClinical Science, 2011
- Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: A pilot studyArchives of Cardiovascular Diseases, 2011
- Time to Treatment for Acute Coronary SyndromesJournal of Cardiovascular Nursing, 2010
- Effect of Door-to-Balloon Time on Mortality in Patients With ST-Segment Elevation Myocardial InfarctionJACC, 2006
- The Interpretation of Random-Effects Meta-Analysis in Decision ModelsMedical Decision Making, 2005